This interview discusses how BCMA-directed CAR T-cell therapy in multiple myeloma may be more effective when administered ...
Every time our body encounters a new disease-causing agent, a crucial defense system called adaptive immunity comes into play ...
MedPage Today on MSN
CAR-like T cells enhance tumor response in gastroesophageal cancer
Liu described the CAR-like T cells as cytokine-activated lymphocytes engineered with the tumor-targeting and -penetrating ...
Patients treated in an outpatient setting who later required admission spent an average of 12.1 days in the hospital, ...
Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery through innovative technology ...
Applied Cells Inc. and Immuneel Therapeutics Private Limited today announced that the companies have entered into a collaboration framework to jointly evaluate application of Applied Cells' MARS(R) ...
A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...
Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with ...
Colleen Mabasa, a patient with multiple myeloma, discusses her CAR T-cell therapy journey and the pivotal role self-advocacy ...
Nona Biosciences inks agreement with Link Cell Therapies to advance CAR-T cell therapies: Cambridge, Massachusetts Monday, January 12, 2026, 11:00 Hrs [IST] Nona Biosciences (Nona ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback